Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
On 6ix: 6ix.com/news/anavex-announces-first-entire-clinical-alzheimers-gene-pathway-data-of-anavexr2-73-at
Watch Anavex Life Sciences' latest callAnavex Life Sciences (NASDAQ:AVXL) Q1 2026 Earnings Call · Replay · Feb 9Read the transcript of Anavex Life Sciences (NASDAQ:AVXL) Q1 2026 Earnings CallAnavex Life Sciences Corp. on 6ix
Earlier from Anavex Life Sciences
- Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
- Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
- Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
- Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
- Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
Later from Anavex Life Sciences
- Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
- Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
- Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
- Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
- Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Follow Anavex Life Sciences into a list and get an email when it puts out news.
Follow Anavex Life Sciences